XNAS 01 May, 2026 5:30 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Joseph G. Oliveto | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 2.26 per share. | 16 Apr 2026 | 36,500 | 446,244 (1%) | 0% | 2.3 | 82,490 | Common Shares |
| Joseph G. Oliveto | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2026 | 679,000 | 679,000 | - | - | Employee Stock Option (right to buy) | |
| Joseph G. Oliveto | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2026 | 453,000 | 453,000 | - | - | Restricted Stock Unit | |
| Lorenz Muller | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2026 | 204,000 | 204,000 | - | - | Employee Stock Option (right to buy) | |
| Lorenz Muller | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2026 | 136,000 | 136,000 | - | - | Restricted Stock Unit | |
| Amit Hasija | CFO & EVP of Corp. Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2026 | 136,000 | 136,000 | - | - | Restricted Stock Unit | |
| Amit Hasija | CFO & EVP of Corp. Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2026 | 204,000 | 204,000 | - | - | Employee Stock Option (right to buy) | |
| David Bharucha | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2026 | 204,000 | 204,000 | - | - | Employee Stock Option (right to buy) | |
| David Bharucha | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2026 | 136,000 | 136,000 | - | - | Restricted Stock Unit | |
| Jeffrey Edward Nelson | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2026 | 204,000 | 204,000 | - | - | Employee Stock Option (right to buy) | |
| Jeffrey Edward Nelson | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2026 | 136,000 | 136,000 | - | - | Restricted Stock Unit | |
| Joseph G. Oliveto | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2026 | 679,000 | 679,000 | - | - | Employee Stock Option (right to buy) | |
| Lorenz Muller | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2026 | 204,000 | 204,000 | - | - | Employee Stock Option (right to buy) | |
| Amit Hasija | CFO & EVP of Corp. Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2026 | 204,000 | 204,000 | - | - | Employee Stock Option (right to buy) | |
| David Bharucha | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2026 | 204,000 | 204,000 | - | - | Employee Stock Option (right to buy) | |
| Jeffrey Edward Nelson | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2026 | 204,000 | 204,000 | - | - | Employee Stock Option (right to buy) | |
| Joseph G. Oliveto | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 2.25 per share. | 07 Jan 2026 | 500 | 346,721 (1%) | 0% | 2.3 | 1,125 | Common Shares |
| Joseph G. Oliveto | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 2.25 per share. | 07 Jan 2026 | 43,000 | 303,721 (1%) | 0% | 2.3 | 96,750 | Common Shares |
| Joseph G. Oliveto | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Dec 2025 | 280,000 | 280,000 | - | - | Employee Stock Option (right to buy) | |
| Joseph G. Oliveto | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Dec 2025 | 66,600 | 199,800 | - | - | Restricted Stock Units | |
| Joseph G. Oliveto | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Dec 2025 | 66,600 | 517,267 (2%) | 0% | - | Common Shares | |
| Joseph G. Oliveto | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Dec 2025 | 280,000 | 583,721 (2%) | 1% | - | Common Shares | |
| Joseph G. Oliveto | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 2.32 per share. | 12 Dec 2025 | 133,054 | 450,667 (1%) | 0% | 2.3 | 308,685 | Common Shares |
| Joseph G. Oliveto | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 1.93 per share. | 12 Dec 2025 | 34,523 | 482,744 (1%) | 0% | 1.9 | 66,629 | Common Shares |
| Lorenz Muller | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Dec 2025 | 100,000 | 250,052 (1%) | 0% | - | Common Shares | |
| Lorenz Muller | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Dec 2025 | 20,100 | 60,300 | - | - | Restricted Stock Units | |
| Lorenz Muller | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Dec 2025 | 100,000 | 100,000 | - | - | Employee Stock Option (right to buy) | |
| Lorenz Muller | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 1.93 per share. | 12 Dec 2025 | 11,180 | 205,406 (0%) | 0% | 1.9 | 21,577 | Common Shares |
| Lorenz Muller | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Dec 2025 | 20,100 | 216,586 (0%) | 0% | - | Common Shares | |
| Lorenz Muller | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 2.32 per share. | 12 Dec 2025 | 53,566 | 196,486 (0%) | 0% | 2.3 | 124,273 | Common Shares |
| Amit Hasija | CFO & EVP of Corp. Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Dec 2025 | 100,000 | 150,000 (0%) | 0% | - | Common Shares | |
| Amit Hasija | CFO & EVP of Corp. Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Dec 2025 | 20,100 | 60,300 | - | - | Restricted Stock Units | |
| Amit Hasija | CFO & EVP of Corp. Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Dec 2025 | 100,000 | 100,000 | - | - | Employee Stock Option (right to buy) | |
| Amit Hasija | CFO & EVP of Corp. Development | Sale of securities on an exchange or to another person at price $ 1.93 per share. | 12 Dec 2025 | 12,245 | 99,848 (0%) | 0% | 1.9 | 23,633 | Common Shares |
| Amit Hasija | CFO & EVP of Corp. Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Dec 2025 | 20,100 | 112,093 (0%) | 0% | - | Common Shares | |
| Amit Hasija | CFO & EVP of Corp. Development | Sale of securities on an exchange or to another person at price $ 2.32 per share. | 12 Dec 2025 | 58,007 | 91,993 (0%) | 0% | 2.3 | 134,576 | Common Shares |
| David Bharucha | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Dec 2025 | 100,000 | 100,000 | - | - | Employee Stock Option (right to buy) | |
| David Bharucha | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Dec 2025 | 100,000 | 163,333 (0%) | 0% | - | Common Shares | |
| David Bharucha | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 2.32 per share. | 12 Dec 2025 | 58,007 | 105,326 (0%) | 0% | 2.3 | 134,576 | Common Shares |
| David Bharucha | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Dec 2025 | 20,100 | 125,426 (0%) | 0% | - | Common Shares | |
| David Bharucha | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 1.93 per share. | 12 Dec 2025 | 12,245 | 113,181 (0%) | 0% | 1.9 | 23,633 | Common Shares |
| David Bharucha | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Dec 2025 | 20,100 | 60,300 | - | - | Restricted Stock Units | |
| Jeffrey Edward Nelson | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Dec 2025 | 20,100 | 62,093 (0%) | 0% | - | Common Shares | |
| Jeffrey Edward Nelson | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Dec 2025 | 100,000 | 100,000 (0%) | 0% | - | Common Shares | |
| Jeffrey Edward Nelson | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Dec 2025 | 20,100 | 60,300 | - | - | Restricted Stock Units | |
| Jeffrey Edward Nelson | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Dec 2025 | 100,000 | 100,000 | - | - | Employee Stock Option (right to buy) | |
| Jeffrey Edward Nelson | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 1.93 per share. | 12 Dec 2025 | 12,245 | 49,848 (0%) | 0% | 1.9 | 23,633 | Common Shares |
| Jeffrey Edward Nelson | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 2.32 per share. | 12 Dec 2025 | 58,007 | 41,993 (0%) | 0% | 2.3 | 134,576 | Common Shares |
| Lorenz Muller | Chief Commercial Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 09 Dec 2025 | 25,000 | 150,052 (0%) | 0% | 0 | Common Shares | |
| Joseph G. Oliveto | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jul 2025 | 66,666 | 347,221 (1%) | 0% | - | Common Shares | |
| Joseph G. Oliveto | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jul 2025 | 66,666 | 66,666 | - | - | Series A Common Warrants (right to buy) | |
| Joseph G. Oliveto | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jul 2025 | 66,666 | 66,666 | - | - | Series B Common Warrants (right to buy) | |
| Joseph C. Papa | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jul 2025 | 100,000 | 100,000 (0%) | 0% | - | Common Shares | |
| Joseph C. Papa | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jul 2025 | 100,000 | 100,000 | - | - | Series B Common Warrants (right to buy) | |
| Joseph C. Papa | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jul 2025 | 100,000 | 100,000 | - | - | Series A Common Warrants (right to buy) | |
| Robert J. Wills | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jul 2025 | 50,000 | 50,000 | - | - | Series A Common Warrants (right to buy) | |
| Robert J. Wills | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jul 2025 | 50,000 | 50,000 | - | - | Series B Common Warrants (right to buy) | |
| Robert J. Wills | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jul 2025 | 50,000 | 65,000 (0%) | 0% | - | Common Shares | |
| Lorenz Muller | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jul 2025 | 66,666 | 175,052 (0%) | 0% | - | Common Shares | |
| Lorenz Muller | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jul 2025 | 66,666 | 66,666 | - | - | Series B Common Warrants (right to buy) | |
| Lorenz Muller | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jul 2025 | 66,666 | 66,666 | - | - | Series A Common Warrants (right to buy) | |
| Debra K. Liebert | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jul 2025 | 16,666 | 16,793 (0%) | 0% | - | Common Shares | |
| Debra K. Liebert | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jul 2025 | 16,793 | 16,793 | - | - | Series A Common Warrants (right to buy) | |
| Debra K. Liebert | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jul 2025 | 16,793 | 16,793 | - | - | Series B Common Warrants (right to buy) | |
| Amit Hasija | CFO & EVP of Corp. Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jul 2025 | 50,000 | 50,000 (0%) | 0% | - | Common Shares | |
| Amit Hasija | CFO & EVP of Corp. Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jul 2025 | 50,000 | 50,000 | - | - | Series A Common Warrants (right to buy) | |
| Amit Hasija | CFO & EVP of Corp. Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jul 2025 | 50,000 | 50,000 | - | - | Series B Common Warrants (right to buy) | |
| David Bharucha | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jul 2025 | 53,333 | 53,333 | - | - | Series B Common Warrants (right to buy) | |
| David Bharucha | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jul 2025 | 53,333 | 63,333 (0%) | 0% | - | Common Shares | |
| David Bharucha | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jul 2025 | 53,333 | 53,333 | - | - | Series A Common Warrants (right to buy) | |
| Joseph C. Papa | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2025 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| Lisa M. Giles | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2025 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| Michael J. Tomsicek | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2025 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| Seth H.Z. Fischer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2025 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| Andrew R. Saik | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2025 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| Robert J. Wills | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2025 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| Stuart M. Duty | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2025 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| Joseph G. Oliveto | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jan 2025 | 399,600 | 399,600 | - | - | Employee Stock Option (right to buy) | |
| Joseph G. Oliveto | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jan 2025 | 266,400 | 266,400 | - | - | Restricted Stock Unit | |
| Lorenz Muller | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jan 2025 | 80,400 | 80,400 | - | - | Restricted Stock Unit | |
| Lorenz Muller | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jan 2025 | 120,600 | 120,600 | - | - | Employee Stock Option (right to buy) | |
| Amit Hasija | CFO & EVP of Corp. Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jan 2025 | 120,600 | 120,600 | - | - | Employee Stock Option (right to buy) | |
| Amit Hasija | CFO & EVP of Corp. Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jan 2025 | 80,400 | 80,400 | - | - | Restricted Stock Unit | |
| David Bharucha | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jan 2025 | 80,400 | 80,400 | - | - | Restricted Stock Unit | |
| David Bharucha | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jan 2025 | 120,600 | 120,600 | - | - | Employee Stock Option (right to buy) | |
| Jeffrey Edward Nelson | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jan 2025 | 120,600 | 120,600 | - | - | Employee Stock Option (right to buy) | |
| Jeffrey Edward Nelson | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jan 2025 | 80,400 | 80,400 | - | - | Restricted Stock Unit | |
| Joseph C. Papa | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Sep 2024 | 80,000 | 80,000 | - | - | Stock Option (right to buy) | |
| Lisa M. Giles | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Aug 2024 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| Michael J. Tomsicek | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Aug 2024 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| Seth H.Z. Fischer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Aug 2024 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| Andrew Saik | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Aug 2024 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| Robert J. Wills | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Aug 2024 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| Stuart M. Duty | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Aug 2024 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| Andrew Saik | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jul 2024 | 80,000 | 80,000 | - | - | Stock Option (right to buy) | |
| Stuart M. Duty | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jul 2024 | 80,000 | 80,000 | - | - | Stock Option (right to buy) | |
| Robert J. Wills | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Debra K. Liebert | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Richard C. Pasternak | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Seth H.Z. Fischer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Mar 2023 | 42,000 | 42,000 | - | - | Stock Option (right to buy) | |
| Joseph G. Oliveto | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2023 | 360,000 | 360,000 | - | - | Employee Stock Option (right to buy) | |
| Lorenz Muller | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2023 | 105,000 | 105,000 | - | - | Employee Stock Option (right to buy) | |
| Amit Hasija | CFO & EVP of Corp. Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2023 | 130,000 | 130,000 | - | - | Employee Stock Option (right to buy) | |
| David Bharucha | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2023 | 185,000 | 185,000 | - | - | Employee Stock Option (right to buy) | |
| Jeffrey Edward Nelson | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2023 | 105,000 | 105,000 | - | - | Employee Stock Option (right to buy) | |
| David Bharucha | Chief Medical Officer | Purchase of securities on an exchange or from another person at price $ 4.69 per share. | 01 Dec 2022 | 7,000 | 10,000 (0%) | 0% | 4.7 | 32,830 | Common Shares |
| David Bharucha | Chief Medical Officer | Purchase of securities on an exchange or from another person at price $ 4.86 per share. | 01 Dec 2022 | 3,000 | 3,000 (0%) | 0% | 4.9 | 14,580 | Common Shares |
| Debra K. Liebert | Director | Purchase of securities on an exchange or from another person at price $ 5.26 per share. | 20 Oct 2022 | 4,000 | 4,000 (0%) | 0% | 5.3 | 21,040 | Common Shares |
| Debra K. Liebert | Director | Purchase of securities on an exchange or from another person at price $ 5.29 per share. | 20 Oct 2022 | 10,000 | 10,000 (0%) | 0% | 5.3 | 52,900 | Common Shares |
| Richard C. Pasternak | Director | Purchase of securities on an exchange or from another person at price $ 5.20 per share. | 20 Oct 2022 | 10,000 | 10,000 (0%) | 0% | 5.2 | 52,000 | Common Shares |
| Michael J. Tomsicek | Director | Purchase of securities on an exchange or from another person at price $ 5.32 per share. | 19 Oct 2022 | 15,000 | 15,000 (0%) | 0% | 5.3 | 79,800 | Common Shares |
| Robert J. Wills | Director | Purchase of securities on an exchange or from another person at price $ 4.93 per share. | 19 Oct 2022 | 15,000 | 15,000 (0%) | 0% | 4.9 | 73,950 | Common Shares |
| Debra K. Liebert | Director | Other type of transaction at price $ 0.00 per share. | 14 Sep 2022 | 127 | 127 (0%) | 0% | 0 | Common Shares | |
| Lisa M. Giles | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jul 2022 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Michael J. Tomsicek | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jul 2022 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Robert J. Wills | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jul 2022 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Debra K. Liebert | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jul 2022 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Richard C. Pasternak | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jul 2022 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Paul F. Truex | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 May 2022 | 45,072 | 0 | - | - | Stock Option (right to buy) | |
| Paul F. Truex | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 May 2022 | 22,870 | 2,659 | - | - | Stock Option (right to buy) | |
| Paul F. Truex | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 May 2022 | 822 | 117 | - | - | Stock Option (right to buy) | |
| Paul F. Truex | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.66 per share. | 31 May 2022 | 822 | 76,780 (0%) | 0% | 2.7 | 2,187 | Common Shares |
| Paul F. Truex | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.54 per share. | 31 May 2022 | 22,870 | 75,958 (0%) | 0% | 1.5 | 35,220 | Common Shares |
| Paul F. Truex | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.54 per share. | 31 May 2022 | 45,072 | 53,088 (0%) | 0% | 1.5 | 69,411 | Common Shares |
| Paul F. Truex | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.12 per share. | 31 May 2022 | 8,016 | 8,016 (0%) | 0% | 1.1 | 8,978 | Common Shares |
| Paul F. Truex | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 May 2022 | 8,016 | 0 | - | - | Stock Option (right to buy) | |
| Paul F. Truex | Director | Purchase of securities on an exchange or from another person at price $ 5.60 per share. | 31 May 2022 | 5,000 | 81,780 (0%) | 0% | 5.6 | 28,000 | Common Shares |
| Joseph G. Oliveto | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Mar 2022 | 500,000 | 500,000 | - | - | Employee Stock Option Grant (right to buy) | |
| Lorenz Muller | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Mar 2022 | 160,000 | 160,000 | - | - | Employee Stock Option Grant (right to buy) | |
| Amit Hasija | CFO & EVP of Corp. Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Mar 2022 | 175,000 | 175,000 | - | - | Employee Stock Option Grant (right to buy) | |
| David Bharucha | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2022 | 330,000 | 330,000 | - | - | Employee Stock Option (right to buy) | |
| Paul F. Truex | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2021 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Lisa M. Giles | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2021 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Michael J. Tomsicek | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2021 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Robert J. Wills | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2021 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Debra K. Liebert | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2021 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Richard C. Pasternak | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2021 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Joseph G. Oliveto | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Mar 2021 | 670,000 | 670,000 | - | - | Employee Stock Option (right to buy) | |
| Lorenz Muller | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Mar 2021 | 200,000 | 200,000 | - | - | Employee Stock Option (right to buy) | |
| Francis Plat | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Mar 2021 | 130,000 | 130,000 | - | - | Employee Stock Option (right to buy) | |
| Amit Hasija | CFO & EVP of Corp. Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Mar 2021 | 240,000 | 240,000 | - | - | Employee Stock Option (right to buy) | |
| Lisa M. Giles | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2020 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Robert J. Wills | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2020 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Lorenz Muller | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Aug 2020 | 5,700 | 49,754 | - | - | Employee Stock Option (right to buy) | |
| Lorenz Muller | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.54 per share. | 26 Aug 2020 | 5,700 | 108,386 (0%) | 0% | 1.5 | 8,778 | Common Stock |
| Paul F. Truex | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2020 | 15,000 | 15,000 | - | - | Stock Option (right to buy) | |
| Paul R. Edick | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2020 | 15,000 | 15,000 | - | - | Stock Option (right to buy) | |
| Michael Tomsicek | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2020 | 15,000 | 15,000 | - | - | Stock Option (right to buy) | |
| Francis Plat | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2020 | 35,000 | 35,000 | - | - | Employee Stock Option (right to buy) | |
| Debra K. Liebert | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2020 | 15,000 | 15,000 | - | - | Stock Option (right to buy) | |
| Amit Hasija | CFO & EVP of Corp. Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2020 | 115,000 | 115,000 | - | - | Employee Stock Option (right to buy) | |
| Richard C. Pasternak | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2020 | 15,000 | 15,000 | - | - | Stock Option (right to buy) | |
| Joseph G. Oliveto | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2020 | 200,000 | 200,000 | - | - | Employee Stock Option (right to buy) | |
| Lorenz Muller | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2020 | 60,000 | 60,000 | - | - | Employee Stock Option (right to buy) | |
| Francis Plat | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2020 | 84,000 | 84,000 | - | - | Employee Stock Option (right to buy) | |
| Amit Hasija | CFO & EVP of Corp. Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2020 | 82,000 | 82,000 | - | - | Employee Stock Option (right to buy) | |
| Joseph G. Oliveto | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.54 per share. | 21 Dec 2019 | 7,400 | 280,555 (1%) | 0% | 1.5 | 11,396 | Common Shares |
| Joseph G. Oliveto | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Dec 2019 | 150,000 | 150,000 | - | - | Employee Stock Option (right to buy) | |
| Joseph G. Oliveto | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Dec 2019 | 7,400 | 113,856 | - | - | Employee Stock Option (right to buy) | |
| Paul F. Truex | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Nov 2019 | 4,000 | 4,000 | - | - | Stock Option (right to buy) | |
| Debra K. Liebert | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Nov 2019 | 19,000 | 19,000 | - | - | Stock Option (right to buy) | |
| Richard C. Pasternak | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Nov 2019 | 19,000 | 19,000 | - | - | Stock Option (right to buy) | |
| Lorenz Muller | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.54 per share. | 01 Oct 2019 | 18,043 | 102,686 (0%) | 0% | 1.5 | 27,786 | Common Shares |
| Lorenz Muller | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Oct 2019 | 2,500 | 87,982 | - | - | Employee Stock Option (right to buy) | |
| Lorenz Muller | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Oct 2019 | 32,528 | 55,454 | - | - | Employee Stock Option (right to buy) | |
| Lorenz Muller | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.54 per share. | 01 Oct 2019 | 32,528 | 84,643 (0%) | 0% | 1.5 | 50,093 | Common Shares |
| Lorenz Muller | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.54 per share. | 01 Oct 2019 | 2,500 | 52,115 (0%) | 0% | 1.5 | 3,850 | Common Shares |
| Lorenz Muller | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Oct 2019 | 18,043 | 32,903 | - | - | Employee Stock Option (right to buy) | |
| Lorenz Muller | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2019 | 35,000 | 35,000 | - | - | Employee Stock Option (right to buy) | |
| Timothy L. Maness | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Sep 2019 | 20,000 | 20,000 | - | - | Employee Stock Option (right to buy) | |
| Amit Hasija | CFO & EVP of Corp. Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Sep 2019 | 147,000 | 147,000 | - | - | Employee Stock Option (right to buy) | |
| Philippe Douville | Chief Scientific Officer | 13 May 2019 | 4,124 | 0 | - | - | Class A-1 Preferred | ||
| Philippe Douville | Chief Scientific Officer | 13 May 2019 | 4,124 | 43,392 (0%) | 0% | - | Common Shares | ||
| Timothy L. Maness | Vice President, Finance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 May 2019 | 46,998 | 46,998 | - | - | Employee Stock Option (right to buy) |